About this trial
the study includes patients with liver cirrhosis irrespective of the stage excluding people with active tumor or other major health issue endangering life, the protocol includes the use of autologous bone marrow derived mononuclear cells harvested from the same patient under local anesthesia ,followed by cell concentration and viability testing , then final product is combined with small volume of 2 cc of Wharton gel exosomes 20 billion per to be administered intravenously.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
active malignancy.
severe sepsis.
pregnancy. -
Trial design
Single group
Treatments tested in this trial
Autologous Bone Marrow Aspirate Concentrate
Procedure/Surgeryusing autologous bone marrow aspirated from iliac crest ,centrifuged and then injected intravenously
Treatment groups
Trial outcomes
Primary outcomes
child-Pugh score for liver cirrhosis
The Child-Pugh score is a clinical tool used to assess the severity and prognosis of chronic liver disease, especially cirrhosis, by evaluating five key factors: total bilirubin, albumin, INR (prothrombin time), ascites, and hepatic encephalopathy, with each getting 1-3 points (1=best, 3=worst). Summing these points categorizes patients into Class A (5-6 points, well-compensated), B (7-9 points, moderately impaired), or C (10-15 points, severe dysfunction), helping guide treatment, predict surgical risk, and manage liver transplant needs. A is minimum and C maximum
child-Pugh score of 3 stages depends on bilirubin level, serum albumin ,prothrombin time ,ascites ,encephalopathy
measurement of prothrombin time, albumin, serum bilirubin level and assess ascites and hepatic encephalopathy
Sponsors and contacts
Click on the lead sponsor to view all of their trials.